A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHAMPION
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 08 Mar 2016 Pooled analysis (n=1692) of 4 trials (NCT00237887, NCT00235820, NCT00691964, NCT00710580) were presented at the 74th Annual Meeting of the American Academy of Dermatology.
    • 08 Mar 2016 Results of a pooled analysis (n=1372) from REVEAL and CHAMPION studies presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 08 Mar 2016 Results of pooled subgroup analysis of patients with psoriasis involving the head region (n=1372) from REVEAL and CHAMPION studies, presented at the 74th Annual Meeting of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top